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Abstract
Peste des petits ruminants virus (PPRV) is a significant pathogen of small ruminants and is prevalent in much of Africa, the
Near and Middle East and Asia. Despite the availability of an efficacious and cheap live-attenuated vaccine, the virus has
continued to spread, with its range stretching from Morocco in the west to China and Mongolia in the east. Some of the
world’s poorest communities rely on small ruminant farming for subsistence and the continued endemicity of PPRV is a
constant threat to their livelihoods. Moreover, PPRV’s effects on the world’s population are felt broadly across many
economic, agricultural and social situations. This far-reaching impact has prompted the Food and Agriculture Organization of
the United Nations (FAO) and the World Organisation for Animal Health (OIE) to develop a global strategy for the eradication
of this virus and its disease. PPRV is a morbillivirus and, given the experience of these organizations in eradicating the
related rinderpest virus, the eradication of PPRV should be feasible. However, there are many critical areas where basic and
applied virological research concerning PPRV is lacking. The purpose of this review is to highlight areas where new research
could be performed in order to guide and facilitate the eradication programme. These areas include studies on disease
transmission and epidemiology, the existence of wildlife reservoirs and the development of next-generation vaccines and
diagnostics. With the support of the international virology community, the successful eradication of PPRV can be achieved.
INTRODUCTION
Peste des petits ruminants (PPR) represents one of the most
important challenges to sustainable small-scale agriculture,
particularly sheep and goat farming, in the developing world
[1]. High mortality epidemics of PPR, combined with long-
term endemicity, threaten the livelihoods of subsistence farm-
ers and undermine the fragile economies that this industry
supports [2, 3]. In a worrying trend, the last 15 years have
seen PPR virus (PPRV) broaden its distribution, with epi-
demics as far apart as Morocco and China [4], including
recent (2016) outbreaks in Georgia and Mongolia. PPRV has
now spread to over 70 countries in Africa, the Near and Mid-
dle East, and Asia, and is currently threatening more than
1.7 billion sheep and goats (80% of the global population) [4]
(Fig. 1). Within this area, 300million low-income families
rely on small ruminants for food and for trade; demand for
small ruminant meat/milk is predicted to increase by 177%
by 2030 [5]. PPR has therefore been highlighted as a signifi-
cant disease in need of immediate global control [4]. The
impact of PPR is perhaps best illustrated from an economic
perspective, as it is estimated to cause $1.45–$2.1 billion
(USD) worth of losses per year [4, 6].
As a result of the clear economic, social and health impacts of
PPR on human populations, the international community, in
particular the Food and Agriculture Organization of the
United Nations (FAO) and the World Organisation for Ani-
mal Health (OIE), is now targeting PPR for eradication [4].
This campaign is justified by the benefits that would accrue
from PPR control, and builds upon the successful eradication
of rinderpest virus, the closely related morbillivirus of large
ruminants. The international community’s success in eradi-
cating rinderpest was based on the readily available, cheap
and effective live attenuated Plowright vaccine, as well as col-
laboration on a global scale. These features are central also to
the eradication strategy for PPR, which comprises a multi-
stage process involving status assessment followed by disease
control (vaccination) leading to PPRV-free status (full details
can be obtained on the FAO and OIE websites (www.fao.org/
ppr/en/ and www.oie.int/animal-health-in-the-world/ppr-
portal/). As was the case with the rinderpest eradication
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programme, there are effective vaccines against PPRV [7, 8]
and good laboratory diagnostic tests [9]. However, much of
our understanding of the virus is based on an assumed simi-
larity to rinderpest virus (RPV) [10]. While certain correla-
tions are likely to be valid, particularly in areas relating to the
physical properties of the virus, the pathogenesis and trans-
mission may differ significantly, while the breadth of host
species susceptible to infection with PPRV has not been well
characterized, as was the case for RPV. The purpose of this
review is to summarize current and future research that can
support the PPRV eradication campaign, through basic and
applied studies in molecular biology, epidemiology and vacci-
nology. While there exists a good basis of support for the con-
trol programmes being set up, more research is required to
ensure the ultimate success of the eradication campaign.
PPRV
PPRV is a paramyxovirus of the genus Morbillivirus, closely
related to measles virus (MeV) (of humans) and the now
eradicated RPV of cattle (Fig. 2). The virus is an enveloped
RNA virus with a non-segmented genome of negative sense.
PPRV virology has been extensively reviewed elsewhere [2, 3,
11, 12]; however, the salient points are that this virus is a
highly infectious pathogen causing an acute febrile illness
within susceptible sheep and goat populations. The associated
disease has high morbidity, with mortality rates approaching
50 to 80% [1]. There is no known arthropod vector, and
transmission is thought to be via aerosol or contaminated
fomites [12].
An effective live attenuated vaccine strain (Nigeria 75/1;
lineage II) was derived in the 1980s [13]. This vaccine is
known to give protection for at least 3 years [8, 10] and has
been used throughout Africa, the Middle East and many
countries in Asia. The major exception is India, where sev-
eral similar vaccine strains, e.g. Sungri 96 (lineage IV), have
been developed and are in widespread use in that country
[7, 14]. However, since PPRV is mono-serotypic there is no
evidence that the original vaccine strain would not be effec-
tive in India, or that the Indian vaccine strains would not be
effective in Africa, the Middle East or other parts of Asia.
Sequence-based phylogenetic analyses have been used to
divide the known isolates of PPRV into four distinct lineages
[15]. There is no evidence that these lineages vary in their
pathogenicity – rather they are a reflection of the distinct geo-
graphical origins of the viruses (allopatricity) and allow lim-
ited conclusions to be drawn as to the origin of new
outbreaks, e.g. it was clear that the virus that caused the first
outbreaks in Africa north of the Sahara was lineage IV, and
so must have come from Turkey or the Middle East, since
only lineages I, II and III were circulating in sub-Saharan
Africa at that time [16, 17].
PPRV VIROLOGY AND EPIDEMIOLOGY:
IMPROVING OUR FUNDAMENTAL
UNDERSTANDING
There have been many advances in morbillivirus research in
the last 10–15 years, e.g. identification of two receptors
Fig. 1. Geographic distribution of PPRV. Adapted from official OIE data on the global prevalence of PPRV. Countries highlighted in red
have had recognized outbreaks of PPRV in the past.
Baron et al., Journal of General Virology 2017;98:2635–2644
2636
Downloaded from www.microbiologyresearch.org by
IP:  130.209.115.82
On: Mon, 12 Mar 2018 12:34:48
CD150/SLAMF1 and Nectin-4 [18, 19], as well as a better
understanding of pathogenesis (reviewed here: [20]). How-
ever, PPRV-specific knowledge still lags behind that of MeV
and RPV. In particular, features such as host-susceptibility,
transmission and field epidemiology remain poorly
characterized.
Examining small ruminant susceptibility
Previous reports have suggested that goats may be more
severely affected than sheep by PPRV infection [21–23].
However, variation in disease severity has also been
observed between different species of goats [24, 25], and
detailed research is required to define this susceptibility and
whether the variation extends to specific features such as
the duration of viral shedding in infected animals, which
will contribute to the dynamics of PPR transmission. If
within-species genetic variation in host susceptibility to dis-
ease is found, as has been shown for other ruminant patho-
gens, such as the sheep lentiviruses that cause ovine
progressive pneumonia [26], the identification of naturally
PPRV-resistant breeds could provide opportunities for
selective breeding. An extensive sheep and goat breed
genome database is available, which was used to show, for
example, that variation in the PPRV epithelial receptor, nec-
tin-4, does not confer differential susceptibility [27], and
this is a promising area for continued research. However,
while completely resistant breeds serve as an important tool
in endemic areas to complement ongoing eradication, the
impact of such animals on PPRV epidemiology (e.g. the
possibility of subclinical spread of the virus) should be con-
sidered carefully.
The role of other species in PPRV epidemiology
There are numerous reports of PPRV infection in animals
other than domestic sheep and goats. Infection of wild
sheep/goats [28–30] and other wild and domestic ruminants
(cattle, buffalo, gazelle and wildebeest) have been reported
[31–34], as well as camels [35] and recently even dogs [36].
If confirmed and shown to be relevant from a transmission
perspective, such observations would be very important due
to the continued existence of transhumance and pastoralism
amongst sheep and goat herders. However, few of these
reports discriminate between (i) species that can be infected
subclinically, seroconvert but do not shed virus (spill-over
or dead-end infections); (ii) species that develop disease and
which actively secrete infectious virus; and (iii) species in
which infection is clinically inapparent but the animal
remains infectious, shedding virus. Even where a specific
pathogenesis has been related to isolated PPRV, as was the
case with camels [37], follow-up investigations in which the
isolated virus has been reintroduced into naïve camels have
not been performed. It is important that such observations
should be extended robustly to correlate pathogenesis, anti-
body responses and virus excretion. The level of virus excre-
tion is the most difficult to determine; however, without this
information it is very difficult to address adequately the
associated risk to the PPR control and eradication cam-
paign. The presence of the disease in wildlife is another area
where additional research is needed. In December 2016, the
disease was diagnosed in several wildlife populations in east-
ern Mongolia, e.g. saiga antelope (Saiga tatarica mongolica),
ibex (Capra sibirica) and goitred gazelle (Gazella subguttor-
osa), with more than 5000 deaths (World Animal Health
Information Database; WAHIS interface). An important
first step in this area is to ensure that the currently available
tests for sero-diagnosis of PPRV are validated in serum
samples from these animal species, e.g. camels, saiga deer
and ibex. With specific reference to the PPRV eradication
campaign, the significance of these infections as a whole
Fig. 2. Morbillivirus genome alignment. A phylogenetic tree comparing the established morbilliviruses with a focus on PPRV (including
field isolates and vaccine strains). Complete genome sequences were used to generate a pairwise tree using the AlignX package within
Vector NTI. Genbank accession numbers and genetic distances from the branch are provided in parentheses. Abbreviations: CDV,
canine distemper virus; CeMV, cetacean morbillivirus; IC, Co^te d’Ivoire (Ivory Coast); FmoPV, feline morbillivirus; MeV, measles virus;
Ng, Nigeria; PDV, phocine distemper virus; PPRV, peste des petits ruminants virus; RPV, rinderpest virus; Su, Sungri; Tu, Turkey. PPRV
genomes highlighted with asterisks are vaccine strains.
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should be carefully evaluated, as they may not significantly
affect the ultimate success of the programme.
Characterizing PPRV transmission
Some basic parameters of the transmission of PPRV remain
to be established. Early studies on RPV established the
period during which live virus was excreted from infected
animals and the level of virus in various excretions, such as
milk, urine and faeces [38]. These studies have never been
carried out on PPRV and, while it is tempting to assume a
similar pattern for related viruses, there are clear differences
between the two diseases which may have significant effects
on the transmission dynamics, notably that PPRV shows
extensive lung pathology in infected sheep/goats, which was
not seen in RPV-infected cattle. Quantitative data should
therefore be acquired to improve our understanding of the
key differences between PPRV and RPV.
Similarly, little is also known about the stability of PPRV in
the environment [10]. In order to provide the required sup-
porting data to the eradication campaign, research must be
conducted on the stability of PPRV in relevant contexts, e.g.
the role of contaminated bedding and fomites in PPRV
transmission by animal movement, or its stability in prod-
ucts such as milk and meat. An important characteristic of
morbillivirus infections is their systemic infection, with the
virus being found in various excretions and bodily fluids
[39], and this pathogenic feature cannot be overlooked in
modelling the transmission of the virus.
Factors affecting herd immunity and determining
vaccination policy
The success of the PPR eradication strategy could depend on
our ability to model virus transmission and epidemiology cor-
rectly. While it is clear that the entirety of a naïve herd can
rapidly become infected by PPRV, our understanding at a
farm-by-farm level, with varying herd-immunities, is much
weaker. Further field studies on PPRV transmission are there-
fore required to define the basic reproduction number (R0)
and effective reproductive number (Rt) (in the context of herd
immunity) of PPRV and to analyse how different environ-
ments, farming intensity, animal replacement rates and pasto-
ral systems influence these values. Knowledge of R0 and Rt is
required to establish the level of herd immunity required to
prevent transmission; in the absence of specific data, the target
immunity levels may only be estimated. Currently, herd
immunity levels of anything from 70 to 90% are widely
quoted as being required to successfully prevent PPR trans-
mission, figures which are rooted in the rinderpest eradication
campaign as much as in more specific PPR studies [40–42].
Studies of this kind have been performed, e.g. in Tanzania
[43] and Pakistan [44], estimating an Rt of 4.0 (range 2.8–6.5)
and a R0 of 6.9, respectively; however, more research is
required to substantiate these findings and extend them to
other farming environments.
Other factors, such as the short economic lifespan of small
ruminants, pastoralism, agricultural production systems,
population density, extensive international trade etc., are
likely to play a significant role in transmission. For example,
based on historical data and epidemiological research on
MeV, it is likely that PPRV epidemics/outbreaks will
become irregular and unpredictable after the eradication
campaign begins [40, 41, 45, 46]. The causes of this irregu-
larity are considered to be linked to exogenous factors, par-
ticularly altering birth rates during vaccination [45]. It will
therefore be important for field epidemiologists to monitor
the effects of the eradication campaign on small ruminant
birth rate, which may increase in relation to herd immunity.
Independently, there is also a requirement for well-con-
trolled transmission studies to facilitate this discussion,
although it is already known that within-herd infection rates
in naïve populations can be 100%, with associated mortality
rates of 50–90% [4, 47].
From a broader perspective, a more detailed understanding
of the trade in small ruminants might also improve our
understanding of PPR transmission. Research in this area
can be used to guide targeted vaccination strategies and may
also help to define the true nature of endemicity from a
virology, epidemiology and pathogenesis perspective. These
resources and research will be particularly important in the
later stages of an eradication campaign, when movement
controls are a critical tool in preventing the spread and re-
emergence of the disease.
PPRV VACCINATION: CURRENT SITUATION
AND FUTURE TRENDS
Implementing thermostable vaccines
One of the key issues in effective implementation of the
existing live PPRV vaccines is their limited thermotolerance,
which requires the maintenance of a cold-chain. For rinder-
pest virus this problem was overcome through use of
specific lyophilized vaccine preparations with high thermo-
tolerance [48]. Freeze-drying using lactalbumin hydrolysate
and sucrose stabilizers increased the robustness of the vac-
cine preparation, allowing short-term storage at tempera-
tures up to 37

C or even 45

C. Similar technologies have
been applied to PPR vaccines [49] and the process appears
to provide good stabilization, e.g. several months at 37

C
[50]. Research in this area must focus on optimizing these
approaches to provide technology that can be directly
applied by commercial producers of the vaccine.
Development and application of PPRV vaccines
There have been repeated calls for the development of a
new generation of PPR vaccines, specifically vaccines capa-
ble of distinguishing vaccinated from infected animals
(DIVA) [7, 51]. Some of the most promising DIVA candi-
dates are recombinant viruses expressing viral surface gly-
coproteins to elicit a protective immune response. Since a
natural PPRV infection also elicits an anti-nucleoprotein
response in animals, these DIVA vaccines theoretically
make the serological response in vaccinated animals dis-
tinguishable from naturally infected animals. This is espe-
cially useful in situations where surveillance is being
Baron et al., Journal of General Virology 2017;98:2635–2644
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implemented at the same time as vaccination. In recent
years several such vaccines have been successfully devel-
oped, particularly using adenovirus [52–55] and goat/
sheep pox vectors [56–58], and some have been tested for
efficacy in conventional PPR challenge studies; however,
their capacity for long-term protection (up to 2 years) has
yet to be determined. For vectored vaccines, the presence
of pre-existing immunity against the vector, i.e. in the case
of capripox combination vaccines [59], has also not been
thoroughly examined in the field. In all these cases, further
research is required to convert their clear potential into
applicable field vaccines. Besides trans-expression of viral
glycoproteins, there have also been approaches taken to
generate recombinant PPRV-based DIVA vaccines, e.g.
negatively marking dominant epitopes in H commonly
detected during sero-surveillance [60]. Two systems for
making recombinant PPRV have been published [61, 62],
offering a promising route for the production of such
novel marker, DIVA or heterologous vaccines. However, it
remains to be seen how effective this approach could be
for PPRV, and how stable these mutations are during live-
vaccine production. Importantly, all of these vaccines con-
stitute ‘genetically modified organisms’ (GMOs), and
therefore adequate planning must be taken before they can
be legally implemented in the field.
Separately, it is also worth considering the age at which vac-
cination can be performed efficaciously. Sheep and goats
have short gestation periods (c. 150 days) and can breed
twice a year. This, combined with their short economic life-
spans in the developing world (c. 3–5 years), means that
populations are highly dynamic, complicating the develop-
ment of the robust herd immunity levels required for eradi-
cation. Younger animals will therefore be a primary target
for vaccination; however, few detailed research data are
available to indicate the age at which they can be vaccinated.
In addition, the duration of protective maternal immunity
provided by an immunized or naturally infected dam is also
unclear, as well as the degree to which this immunity can
prevent effective vaccination. These are clearly areas where
specific research needs to be performed to provide data to
support vaccination, and ultimately eradication.
PPRV co-morbidities and the control of other
diseases of small ruminants
Co-morbidities are a frequent problem in small ruminant
farming, e.g. in one study in Turkey, PPRV, bluetongue
virus and sheep/goat pox virus were all identified in the
same flock of sheep and goats [63]. There is also evidence
for co-circulation of PPRV with other pathogens such as
B. anthracis and foot and mouth disease virus (FMDV)
[64] or Brucella spp [65]. Another concern is that viruses
such as Rift Valley fever virus (RVFV) or Nairobi sheep
disease virus (NSDV) may replicate preferentially in PPR-
affected animals. MeV infection has been shown to cause
profound immune suppression as a result of lymphopenia,
cytokine imbalances and deficient expansion of PBMCs
[66]. Immune suppression was also seen in RPV-infected
animals, even those exposed only to the vaccine [67].
Research is therefore required to examine whether PPRV
similarly causes long-term immune suppression and
whether the vaccine strains have any such effect, even if
transient, which may impact on the efficacy of co-admin-
istered vaccines.
Nevertheless, a well-orchestrated PPR eradication campaign
could provide an excellent platform for the control of other
small ruminant diseases. The major cost of any vaccination
campaign is normally that of vaccine delivery. Significant
benefits and cost improvements could be achieved through
simultaneous vaccination against several small ruminant dis-
eases. This could be addressed either by recombinant vaccines
such as the capripox/PPRV vaccine [59] or by combined vac-
cination against PPR and sheep goat pox, which has already
been shown to be effective [58]. Integrated control campaigns
of this kind are already being implemented in some countries,
e.g. in Morocco for PPR and sheep pox [68]. However, as
mentioned above, this approach raises concerns about the
possible interactions between co-administered vaccines. For
this type of approach to be generally implemented in the PPR
vaccination or eradication strategy, further research is needed
to determine the safety and efficacy of different combinations
of these vaccines.
DIAGNOSTICS – EVERYDAY APPLICATION
AND FUTURE INNOVATION
The existing diagnostic platforms to support PPR eradica-
tion range from commercially available ELISAs and RT-
PCRs to gold-standard VNTs. These assays serve to detect
either the virus directly (either through isolation of infec-
tious virus or via detection of viral antigen or genome) or to
detect the animal’s response to infection (primarily through
virus-specific antibody responses). Although robust tools
exist, there is still a need for research to improve and adapt
existing tests to match various situations that may arise dur-
ing the implementation of the eradication campaign.
Novel tools in the pipeline
Recent developments include a lateral flow device (pen-side
test) for rapid-detection of PPRV in the field [69]. This test
is proving particularly useful in field situations where there
is poor access to laboratory diagnostics, either through geo-
graphical restrictions or political instability, and allows
more rapid decisions about the implementation of control
measures. The recently established viral-pseudotype system
for PPRV, which permits detection of virus-specific anti-
bodies without the need for live virus, is also a noteworthy
development [70]. This alternative to classical VNT assays
could prove particularly useful during an eradication cam-
paign for those diagnostic laboratories that do not have the
facilities to handle high-containment pathogens such as
PPRV. The development of the pseudotype-based assay for
neutralizing antibodies highlights a hitherto unexplored
aspect of ‘gold-standard’ live virus-based VNTs. Morbillivi-
rus infections may induce cross-neutralizing antibodies, and
hence the detection of a neutralizing antibody titre in cattle
Baron et al., Journal of General Virology 2017;98:2635–2644
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against PPRV by live virus-based VNT is not conclusive
evidence of PPRV infection; the animal may have been
exposed to PPRV, RPV or CDV, all of which may induce
anti-PPRV neutralizing or cross-neutralizing antibodies [70,
71]. The recent development of a helper cell-dependent
recombinant PPRV has also yielded a promising, yet bio-
safe, source of viral antigen for future diagnostics, since this
system produces replication-incompetent virus [72].
Future perspectives on monitoring the virus in the
field
Sequencing and molecular epidemiology will play an effec-
tive role in PPR control and eradication. Existing phyloge-
netic analysis of PPRV focuses on relatively short regions in
the N and F genes; however, it is possible that these may
prove insufficiently variable in the future, should one line-
age, e.g. lineage IV, predominate. Future research should
therefore focus on insuring against such an eventuality.
One option is to concentrate analysis on the ectodomain
region of the H ORF, as is the case for MeV [73], since
these data can also be translated into functional information
on receptor binding [74] or antigenicity [75], while still
providing sufficient data to cluster the viruses phylogeneti-
cally along similar lines to the existing N- and F-based sys-
tems (Fig. 3). Logically, however, it may be beneficial to
plan strategically for entire genome sequencing, to allow
detailed monitoring of any ongoing PPRV epidemic. This
genome-wide approach was shown recently to be essential
for identifying the origin of a measles outbreak at the 2010
Vancouver Winter Olympic Games [76–78]; furthermore,
full PPRV genome sequences, including vaccine sequences,
are already available to support this effort [79, 80] (Table 1
and Fig. 2). It is also possible that a PPRV eradication cam-
paign could drive an evolutionary reduction in viral patho-
genesis in the field, complicating surveillance and detection
mechanisms and undermining the success of the strategy.
This has been suggested as a potential explanation for the
‘mild’ rinderpest strains reported in East Africa towards the
end of that eradication campaign [81]. Future research in
this area must complement both in vivo experimentation
and transmission studies with ongoing molecular epidemi-
ology and genome-wide sequencing endeavours in order to
adequately address these risks.
Separately, in countries where PPR is endemic, there is a need
to develop low-cost diagnostic tests or simple tests that can be
applied in the field or in low-technology situations. If the
global PPR strategy recommends combining PPR control with
control of other diseases of small ruminants, a cost-effective,
multi-disease diagnostic test would be very useful for simulta-
neous surveillance for all the target diseases. These multi-dis-
ease diagnostic tests may also be necessary during the final
stages of the eradication programme, when PPR-like disease
symptoms must be investigated to rule out virus re-incursion
and provide robust differential diagnostics.
Fig. 3. A phylogenetic tree comparing PPRV haemagglutinin amino
acid sequences. Isolates from all four recognized genetic lineages (I–
IV) of PPRV are represented and cluster accordingly. This pairwise
tree was constructed using the AlignX package within Vector Nti, with
Kimura’s correction. Genetic distances from the branch are provided
in parentheses; please refer to Table 1 for Genbank accession
numbers.
Table 1. Currently available PPRV genome sequences ordered by
genetic lineage and year of virus isolation
GenBank
accession no
Country of
origin
Lineage Year of
isolation
Similarity to
AJ849636 (%)
KP789375 Senegal I 1969 89
EU267273 Co^te
d’Ivoire
I 1989 89
KR781450 Benin II 1969 92
HQ197753* Nigeria II 1975 92
EU267274 Nigeria II 1976 93
KR781451 Co^te
d’Ivoire
II 2009 92
KJ466104 Ghana II 2010 92
KR781449 Benin II 2011 95
KJ867543 Uganda II 2012 93
KR828814 Nigeria II 2012 97
KM212177 Senegal II 2013 91
KU236379 Liberia II 2015 92
KJ867545 UAE III 1986 87
KJ867540 Ethiopia III 1994 89
KM463083 Kenya III 2011 93
KR140086 India IV 1994 98
KF727981* India IV 1996 98
AJ849636 Turkey IV 2000 100
FJ905304 China IV 2007 97
JF939201 China IV 2007 97
KC594074 Morocco IV 2008 90
JX217850 China IV 2008 97
KJ867541 Ethiopia IV 2010 91
KR828813 Nigeria IV 2013 97
KM091959 China IV 2013 97
KR261605 India IV 2014 97
KT270355 India IV 2014 97
KT633939 China IV 2015 96
KX354359 China IV 2015 97
KX033350 India IV 2016 97
*Denotes vaccine strain.
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SOCIO-ECONOMIC IMPACT
Socio-economic studies into the impact of PPRV on small
ruminant production and livelihoods should not be over-
looked, as these studies will assist in advocating for invest-
ment in the PPR Global Eradication Programme. Despite
increased attention and laboratory research on PPRV in the
last 10–15 years, we neither fully understand nor publicize
the impact of this disease on the livelihoods of small rumi-
nant keepers and national economies across the world. In
order to leverage funding for the research detailed in this
review, we must highlight the role and importance of goats
and sheep within agriculture, e.g. by examining the multiple
uses and services they provide as well as the roles they play
in different farming systems. A better appreciation of the
impact of socio-economic factors on PPR vaccination is also
needed, e.g. the incentives and disincentives associated with
small ruminant production and how they influence partici-
pation in eradication campaigns. At present an in-depth
understanding of this balance is lacking from both the ser-
vice providers’ and livestock owners’ perspective, especially
in areas directly affected by PPRV. Developing better ana-
lytical approaches to estimate and compare all products and
services, and how these are affected by PPRV, will help to
highlight the true worth of small ruminants and the impor-
tance of research that supports the eradication campaign.
EXAMINING THE POTENTIAL FOR INTER-
SPECIES (AND ZOONOTIC) TRANSMISSION OF
MORBILLIVIRUSES
There is one additional point for consideration across the
research community, the consequences and impact of which
may lie downstream of PPRV’s eradication. Immune
responses to morbilliviruses show significant levels of cross-
protection against infection with other species of morbillivi-
ruses [13, 82]. Accordingly, the eradication of one species of
morbillivirus and the subsequent cessation of vaccination
may have long-term consequences on host immunity to
zoonotic infections with other morbilliviruses. It has been
suggested that rinderpest eradication and the cessation of
vaccination may have played a role in the ongoing spread of
PPR [3, 47]. Future studies should investigate whether there
is indeed a causal link, for example by examining the effect
of removing cross-protective antibodies from host popula-
tions. The recent spread of PPR may be due to other factors
such as better surveillance, a shift in veterinary focus to sus-
tainable small ruminant production, increased trade in
ruminants over larger distances, or increased regional politi-
cal instability. There are fears that other morbilliviruses
(known or emerging) may colonize newly available ‘vacated
niches’ [83]. Post-PPRV eradication, the world’s cattle,
sheep and goat populations would lack cross-protective
immunity to morbillivirus infection. Canine distemper virus
(CDV), a virus with an almost global distribution, is capable
of causing significant disease in a broad range of hosts,
including non-human primates [84, 85]. CDV can rapidly
adapt to use the human form of the morbillivirus receptor
(SLAMF1) in vitro [86], raising concerns about the ease
with which these viruses can effectively jump hosts. Indeed,
serological responses to CDV were described recently in
Tanzanian cattle [71]. In addition, a new spectrum of previ-
ously uncharacterized morbilliviruses has been identified in
global bat and rodent populations [87], as well as a specific
new morbillivirus in domestic cats [88]. There is therefore a
critical requirement to develop novel approaches for assess-
ing the risk of such transmission events taking place, for
example by defining the capacity for animal morbilliviruses
to interact with receptors from target species and by assess-
ing the degree of cross-protection afforded by neutralizing
antibodies. By extension, this work would inform our
approach to protecting human health following the global
eradication of measles.
SUMMARY AND CONCLUSIONS
There are compelling animal health, economic and social
reasons to support the FAO/OIE-led PPR Global Eradica-
tion Programme. Alleviating the effect of PPR will have a
considerable impact on the sustainability of small ruminant
agriculture in many low-income countries whilst simulta-
neously addressing the ubiquitous need for an increased
and reliable source of animal protein. To facilitate the deliv-
ery and success of the eradication programme there are
many areas, including those described above and
highlighted in Box 1, where applied and basic research can
provide support. It is important to note that little of this
work requires the development of new technologies, or even
the application of the very latest technologies, but rather the
careful application of classical virology and epidemiology to
provide quantitative data to support those coordinating the
eradication of this important livestock disease.
Box 1. Key research priorities
. Determining the role of atypical hosts in PPRV epidemi-
ology (i.e. species other than sheep and goats).
. Characterizing the effective reproductive number (Rt) of
PPRV in various environments.
. Ensuring effective and broad implementation of thermo-
stable vaccine technology, along with good manufacturing
practice (GMP).
. Improving our understanding of vaccination efficacy in
young animals.
. Developing a DIVA vaccine with associated and validated
differential diagnostic tests.
. Refining the targets for molecular epidemiology and
developing validated partner technologies.
. Increasing the scope and application of in-field
diagnostics.
. Examining the potential for inter-species morbillivirus
transmission.
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